Overview

A Study of Tor Kinase Inhibitor in Advanced Tumors

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca